Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — H1 FY2021 Earnings Presentation
11 slides from Atomo Diagnostics's earnings presentation, Feb 23, 2021
Slide 1: FY21 Interim Results Presentation
This announcement was authorised by John Kelly, Managing Director For personal use only Atomo Diagnostics Limited 701 – 703 Parramatta Road Leichhardt NSW 2040 Australia FY21 Interim Results Presentation 23 February 2021 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on the opportunity outlined in this presentation and no representation or warranty is made in information available as at the date of this presentation. The information in this presentat
Slide 3: Investment Case
INVESTMENT CASE For personal use only A proven innovator – commercialised the world’s first fully integrated, blood-based rapid test devices Emerging market participant with 3.5m devices sold globally and a further 2m contracted ‘Best in class’ solutions based on Atomo’s award winning rapid test dev
Slide 4: Key Financial Metrics - Strong top-line growth
K E Y F I N A N C I A L M E T R I C S 1.- S t r o n g t o p - l i n e g r o w t h For personal use only Revenue Gross Profit GP Margin Drivers Revenue: $4.58m $2.52m 55% • COVID-19: Sales to NG Biotech & direct to the Australian market • HIV: Mylan sales into S. Africa 389% 278% 1,300bps &other coun
Slide 5: Key Business Highlights - Growing international recognition
KEY BUSINESS HIGHLIGHTS – Growing international recognition For personal use only Access Bio Australian COVID- HIV facility Partnership 19 progress certified Agreement to supply 2m COVID-19 antibody test COVID-19 Antibody RDT South African HIV sales commenced. devices into US (take or facility certi
Slide 6: Business Units Summary
BUSINESS UNITS SUMMARY For personal use only COVID-19 HIV OEM Revenue - $2.61m Revenue - $0.77m Revenue - $1.10m • Access Bio – agreement signed to supply • PrEP Health agreement - signed for • Production increase – responding to 2m devices by 30 Sept 2021 (take or pay). distribution of the Atomo HI
Slide 7: Underlying P/L & Cashflow - Scale benefits materialising
U N D E R LY I N G P / L & C A S H F L O W – S c a l e b e n e f i t s m a t e r i a l i s i n g For personal use only • Significant revenue growth of 389% generated by: • $2.61 million from continued customer demand for COVID-19 point of care antibody testing devices, including sales of Atomo devic
Slide 8: Balance Sheet - Well capitalised
BALANCE SHEET – Well capitalised For personal use only • Cash of $24.69 million as at 31 December 2020 and no debt, putting the company in a strong position to continue to invest in growth • Product manufacturing and build up of inventory in anticipation of continued strong growth of COVID-19 rapid
Slide 9: 2H21 - Key Priorities
2H21 – KEY PRIORITIES For personal use only • Following delivery of two containers to-date, ramp up supply of Atomo devices to Access Bio under the take or pay contract for rapid antibody tests to the US market. • FDA Emergency Use Authorisation approval of Access Bio’s COVID-19 rapid antibody tests
Slide 10: COVID - Here to Stay?
C O V I D - 1 9 – H E R E T O S TAY ? For personal use only 10
Slide 11: For personal use only
For personal use only John Kelly Managing Director john.kelly@atomodiagnostics.com +61 401 922 279 atomodiagnostics.com